Transparency Market Research is Published
new Market Report “Atrial Fibrillation Market (Pharmacological and
Non-Pharmacological Treatment, Electric Cardioversion, Radiofrequency, Cryo,
Laser and Microwave Catheter Ablation, Maze Surgery, Anti-Coagulant and
Anti-Arrhythmic Drugs) - Global Industry Analysis, Size, Share, Growth, Trends
and Forecast, 2013 - 2019," . The global market for
atrial fibrillation was valued at USD 6.1 billion in 2012 and it is
expected to reach an estimated value of USD 14.8 billion in 2019,
growing at a CAGR of 13.4% from 2013 to 2019.
Browse
the full report with Complete TOC at http://www.transparencymarketresearch.com/atrial-fibrillation-market.html
Rising global base of geriatric population inducing an accelerated growth
in the incidence rates of atrial fibrillation is one of the highest
impact-rendering drivers for this market. In addition, favorable results exhibited
by clinical trials promoting combined pharmacological therapy such as the
HARMONY trial and rising prevalence of disorders causing atrial fibrillation
such as hypertension and obesity will also serve the market as drivers. The
future growth of this market will be ensured by the introduction of advanced
treatment procedures such as hybrid ablation and the rising prevalence of
atrial fibrillation in emerging Asian economies.
On account of the fact that pharmacological treatment procedures are more
frequently administered to the patients suffering from atrial fibrillation and
are a cheaper alternative to non-pharmacological procedures, pharmacological
procedures held the majority of market share in 2012. With the introduction of
new drugs such as Bristol Myer Squibb's NTC-801, Merck's Vernakalant,
Boehringer Ingelheim's Pradaxa, the market share of pharmacological treatment
procedures is expected to further increase by 2019.
The non-pharmacological treatment market was led by the catheter ablation
market and its market share was valued at over 45% in 2012. The introduction of
new catheter ablation systems such as CardioFocus's HeartLight Endoscopic
Ablation System (EAS) laser ablation catheter, Endosense's TactiCath and
Biosense Webster's ThermoCool SmartTouch, will help the catheter ablation
market to further enhance its market share by 2019.
The radiofrequency based catheter ablation treatment for atrial
fibrillation market led the catheter ablation market in terms of market share
in 2012 majorly on account of the facts that it has a relatively lower
procedural duration and cost and has high success rates associated with it.
High prevalence of atrial fibrillation coupled with the availability of
high disposable incomes amongst patients and sophisticated healthcare
infrastructure, has led the North American atrial fibrillation market to hold
the majority of the market share in 2012. However, this region is expected to
lose its market share to relatively faster
growing Asia-Pacific region.
Some of the key players of this market include Boehringer Ingelheim,
Bristol-Myers Squibb/Pfizer, Bayer/Johnson & Johnson, Medtronic, Inc., St.
Jude Medical, Inc. and AtriCure, Inc.
The global atrial fibrillation market is categorized into the following segments:
- Atrial Fibrillation Market, by Treatment Types
- Pharmacological Treatment
- Anti-Arrhythmic Drugs
- Anti-Coagulant Drugs
- Non-Pharmacological
Treatment
- Catheter Ablation
- Radiofrequency Based
- Cryoablation Based
- HIFU (High Intensity Focused Ultrasound) Based
- Microwave Based
- Laser Based
- Maze Surgery
- Electric Cardioversion
- Atrial Fibrillation Market, by Geography
- North
America
- Europe
- Asia-Pacific
- Rest
of the World (RoW)
Blogs :
No comments:
Post a Comment